Loading patent…
AssigneeCentro de Ingenieria Genetica y Biotecnologia
InventorsDiógenes Quintana Vázquez, Tamara Menendez Medina, Anabel Álvarez Acosta, Yoelys Cruz Leal, Gerardo Enrique Guillen Nieto
Estimating the term…
The present invention is related with the field of Biomedicine. It comprises the engineering of the Pertactin protein (Prn) and using it as part of bacterial vaccines, and more precisely, as part of acellular vaccines against Bordetella pertusis. The engineered Prn molecules comprise on their structure polimorfisms from different B. pertussis strains, and induce immune responses with protective capacity and opsonophagocytic activity when assayed as vaccines, higher than that generated by other pre-existing vaccines. The engineered Prn variants of the present invention are applicable in human and veterinary medicine.
An isolated polynucleotide sequence coding for a pertactin (Prn) engineered protein, wherein said isolated polynucleotide sequence codes for up to the first 300 amino acids proximal to the N-terminal end of a given type of natural, mature Prn (PrnX300) and an amino acid sequence comprising up to the last 620 amino acids proximal to the C-terminal end of a given type of natural, mature Prn (PrnY620), resulting in an engineered PrnX300-PrnY620 pertactin, and wherein the polynucleotide sequence comprises SEQ. ID. NO:
Dependencies are inferred from the claim text.